The DOI matches its Crossref record.
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies
Abstract
Objective: To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs). Methods: A Freedom of Information Act request was submitted for all cases of PML within the Food and Drug Administration Adverse Event Reporting System database. ARD cases were selected for further analysis. Results: A total of 34 confirmed cases of PML in the setting of ARDs were identified: 17 had systemic lupus erythematosus, 10 had rheumatoid arthritis, 4 had vasculitis, and 3 had dermatomyositis. Fifteen of these patients were treated with one or more biologic agents: 14 received rituximab (RTX), 6 received anti–tumor necrosis factor (anti‐TNF) therapy (5 treated with anti‐TNF agent prior to RTX). Four RTX‐treated patients were not receiving additional immunosuppressive therapy at the time of PML onset, other than an antimalarial drug and/or low‐dose glucocorticoids; all others who were receiving a biologic agent were also receiving one or more synthetic disease‐modifying agents. All but 1 patient receiving a biologic agent had at least 1 potential confounding factor for the diagnosis of PML. The remaining 19 confirmed cases of PML among ARD patients were treated with synthetic disease‐modifying antirheumatic drugs only, 14 of whom had received an alkylating agent. Conclusion: PML has been reported in patients with ARD treated with various immunosuppressive agents. The limitations of this study preclude definitive attribution of causality. While the paucity of confirmed cases recently exposed to anti‐TNF therapy suggests a causal relationship is unlikely, a specific signal is emerging with regard to rituximab and PML. Although this is a rare adverse event associated with RTX therapy, the devastating nature of PML mandates continued vigilance, particularly in patients with current or prior exposure to an alkylating agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Danza, A., & Ruiz-Irastorza, G. (2013) · Lupus · doi:10.1177/0961203313493032 · Cited by 359
CNS Demyelination with TNF-α Blockers
Kemanetzoglou, E., & Andreadou, E. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0742-1 · Cited by 319
Myasthenia gravis: an update for the clinician
Sieb, J. P. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12217 · Cited by 283
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Metadata
- Authors
- Molloy, E. S., & Calabrese, L. H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-08-27
- Volume
- 64
- Issue
- 9
- Pages
- 3043-3051
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1966062801
- Cited by
- 191
- References
- 0
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies. https://app.cochat.ai/papers/10.1002/art.34468
- The paper
- Molloy, E. S., & Calabrese, L. H. (2012). Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies. Arthritis & Rheumatism. https://doi.org/10.1002/art.34468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.